A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
Gemcitabine is considered one of the standard drugs for advanced pancreatic cancer and is
approved by the FDA to treat it. Cabozantinib is a new drug that has demonstrated
effectiveness against pancreatic cancer in laboratory experiments, especially when given with
gemcitabine. Initial studies with cabozantinib in pancreatic cancer have shown some activity
against the disease. The purpose of this study is to determine the safest and highest dose of
cabozantinib that can be given together with standard doses of gemcitabine in patients with
pancreatic cancer. This study will determine the safety and tolerability of this two drug
combination.
Phase:
Phase 1
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center